Login to Your Account



Clinic Roundup


Wednesday, June 1, 2011
Vivus Inc., of Mountain View, Calif., presented several posters at the European Congress on Obesity in Istanbul, Turkey, including data that showed Qnexa (phentermine/topiramate) reduced progression to Type II diabetes and improved glycemic status in patients defined as prediabetics at baseline. In the prediabetic population from the CONQUER study, significantly more Qnexa-treated patients achieved normal blood sugar levels (p = 0.0016) and significantly more patients in the placebo arm progressed to Type II diabetes (p = 0.0253). Qnexa was rejected by the FDA last year, but Vivus plans to resubmit a new drug application in the fourth quarter of this year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription